HomeCompareBNOX vs MRK

BNOX vs MRK: Dividend Comparison 2026

BNOX yields 790.20% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BNOX wins by $2499878.52M in total portfolio value
10 years
BNOX
BNOX
● Live price
790.20%
Share price
$0.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2499878.58M
Annual income
$2,001,595,404,407.55
Full BNOX calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — BNOX vs MRK

📍 BNOX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNOXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BNOX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BNOX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BNOX
Annual income on $10K today (after 15% tax)
$67,167.13/yr
After 10yr DRIP, annual income (after tax)
$1,701,356,093,746.42/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, BNOX beats the other by $1,701,356,085,418.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BNOX + MRK for your $10,000?

BNOX: 50%MRK: 50%
100% MRK50/50100% BNOX
Portfolio after 10yr
$1249939.32M
Annual income
$1,000,797,707,102.85/yr
Blended yield
80.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

BNOX
Analyst Ratings
4
Buy
Consensus: Buy
Price Target
$6.00
+2270.6% upside vs current
Range: $6.00 — $6.00
Altman Z
-82.3
Piotroski
5/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BNOX buys
0
MRK buys
0
No recent congressional trades found for BNOX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNOXMRK
Forward yield790.20%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$2499878.58M$56.8K
Annual income after 10y$2,001,595,404,407.55$9,798.13
Total dividends collected$2460392.87M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$6.00$128.54

Year-by-year: BNOX vs MRK ($10,000, DRIP)

YearBNOX PortfolioBNOX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$89,720$79,020.15$11,206$366.19+$78.5KBNOX
2$758,589$662,588.76$12,650$502.35+$745.9KBNOX
3$6,047,418$5,235,727.31$14,407$694.19+$6.03MBNOX
4$45,478,990$39,008,252.73$16,585$967.82+$45.46MBNOX
5$322,828,490$274,165,970.92$19,342$1,363.89+$322.81MBNOX
6$2,164,251,074$1,818,824,589.26$22,913$1,947.19+$2164.23MBNOX
7$13,711,496,364$11,395,747,714.83$27,662$2,823.89+$13711.47MBNOX
8$82,145,270,460$67,473,969,350.51$34,159$4,173.35+$82145.24MBNOX
9$465,685,208,688$377,789,769,296.29$43,337$6,308.80+$465685.17MBNOX
10$2,499,878,577,704$2,001,595,404,407.55$56,776$9,798.13+$2499878.52MBNOX

BNOX vs MRK: Complete Analysis 2026

BNOXStock

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.

Full BNOX Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this BNOX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BNOX vs SCHDBNOX vs JEPIBNOX vs OBNOX vs KOBNOX vs MAINBNOX vs JNJBNOX vs ABBVBNOX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.